anti-ror1 antibody-drug conjugate im-1021
anti-ror1 antibody-drug conjugate im-1021: developed by 1 company · 1 clinical trial tracked.
anti-ror1 antibody-drug conjugate im-1021 evidence translation
What we can confirm
1 tracked trial
What it means
What to watch
Prepared research question
How could anti-ror1 antibody-drug conjugate im-1021 → IMNM affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Immunome Inc. (IMNM) Solid Malignancies | Phase 1 |
Clinical Trials (1)
A Phase 1 Study of IM-1021 in Participants With Advanced Malignancies
Primary endpoint: Safety and tolerability of IM-1021 in participants with advanced lymphomas and advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)
Frequently asked questions
Who is developing anti-ror1 antibody-drug conjugate im-1021?
anti-ror1 antibody-drug conjugate im-1021 is being developed by Immunome Inc..
How many clinical trials involve anti-ror1 antibody-drug conjugate im-1021?
BioSniper tracks 1 clinical trial involving anti-ror1 antibody-drug conjugate im-1021.